Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Who really benefits from IO? Can we identify subsets that benefit and how to measure?

Date

11 May 2023

Session

Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Topics

Clinical Research; Cancer Biology; Tumour Immunology; Translational Research; Immunotherapy

Tumour Site

Breast Cancer

Presenters

Justin Balko

Authors

J. Balko

Author affiliations

VUMC - Vanderbilt University Medical Center, Nashville/US

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

11 May 2023

Benefits of IO in early and metastatic breast cancer

Presenter: Isabel Pimentel

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

Can we predict and manage toxicity in the real world?

Presenter: Rebecca Dent

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

What’s on the horizon for immunotherapy for TNBC?

Presenter: Giampaolo Bianchini

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

Q&A and discussion

Presenter: To be Announced

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Webcast